Doctors Welcome Budget 2024 Decision to Exempt 3 Cancer Drugs from Customs Duty

The Union Budget 2024 has announced the exemption of three critical cancer drugs from customs duty. This decision has been warmly welcomed by doctors and cancer treatment advocates who see it as a crucial step towards making life-saving medications more affordable and accessible.

The exemption applies to three specific cancer drugs that are widely used in the treatment of various types of cancer. By removing customs duty, the government aims to lower the overall cost of these drugs, which are often expensive due to import tariffs and taxes.

Dr Anil Gupta, an oncologist based in Delhi, praised the decision, stating, “This is a momentous step towards reducing the financial burden on cancer patients. The high cost of treatment has been a significant barrier for many, and this exemption will make these essential drugs more accessible.”

Cancer treatments often come with a hefty price tag, placing a considerable financial strain on patients and their families. By exempting these drugs from customs duty, the government is expected to drive down the cost of treatment, providing much-needed relief to those battling cancer.

The move is anticipated to benefit thousands of patients who rely on these drugs for their treatment regimen. Families who previously struggled to afford these medications can now look forward to reduced financial pressure.

The healthcare community has responded positively to the budgetary decision. Leading medical associations and advocacy groups have expressed their support, highlighting the importance of making critical medications more affordable.

Dr. Rina Mehta, a cancer researcher and advocate, commented, “This is a significant victory for patient rights and public health. It reflects the government’s commitment to improving cancer care and addressing the high costs associated with it.”

The Finance Ministry’s decision to exempt these drugs from customs duty is part of a broader effort to make healthcare more affordable and accessible. The government has acknowledged the rising costs of cancer treatment and aims to alleviate some of the financial burdens associated with critical medications.

A ministry spokesperson noted, “Our goal is to support patients by reducing the cost of essential treatments. By exempting these three cancer drugs from customs duty, we hope to contribute to better health outcomes and support the ongoing fight against cancer.”

The exemption is expected to set a precedent for future budget decisions related to healthcare and pharmaceuticals. It underscores the need for continued efforts to address the high costs of medical treatments and ensure that essential drugs are within reach for all patients.

The Union Budget 2024’s decision to exempt three vital cancer drugs from customs duty marks a positive development in the fight against cancer. By reducing the cost of these medications, the government is taking a significant step towards making life-saving treatments more accessible to patients across the country. The move has been met with widespread approval from doctors and healthcare advocates, who view it as a meaningful contribution to improving cancer care.